Supplement: Assessing the Cost of Rheumatoid Arthritis :The Scientist [2007-05-01]


	The article you are attempting to read is Premium content which is only available to our online subscribers.

Subscribing to The Scientist is easy and inexpensive.

And you can choose from many options. Try us out with an online day pass starting at only $4.95. Or, get it all with unlimited online access to The Scientist Archive and door-to-door delivery of our monthly print magazine.


	The Scientist also offers site licenses to institutions and organizations. When your librarian adds The Scientist to the library's collection, you can get unlimited online access through your place of work or study. Recommend The Scientist today



Supplement: Assessing the Cost of Rheumatoid Arthritis In England and Wales, rheumatoid arthritis (RA) affects approximately 400,000 people, or 0.5-1% of the population. Those figures come from the "Final Appraisal Determination: Adalimumab, Etanercept, and Infliximab for the Treatment of Rheumatoid Arthritis," published in November last year, by the National Institute for Health and Clinical Excellence (NICE), which describes itself as "the